Clearant, Inc. Expands Addressable Market For Orthopedic Allograft Surgeries To Include Both Soft Tissue And Bone Implants
LOS ANGELES--(BUSINESS WIRE)--Aug. 3, 2006-- New Products Expand Product Opportunities to Markets Generating More Than $350 Million in Sales from $100 Million Previously. Clearant, Inc. (OTCBB:CLRI) today announced that it has expanded its product portfolio of allograft implants available through its direct sales force to include Clearant Process(R) sterile soft tissue implants for allograft sport medicine surgeries. Clearant now offers its sterile implants for both soft tissue and cervical spinal bone allograft surgeries through its direct distribution channel. By expanding its direct distribution initiative to include both soft and cervical spinal bone implants, Clearant has increased its addressable market from $100 million or more per year (for cervical spinal implants) to $350 million or more per year (for both soft tissue and cervical spinal implants).